zonisamide has been researched along with Protein Aggregation, Pathological in 1 studies
Zonisamide: A benzisoxazole and sulfonamide derivative that acts as a CALCIUM CHANNEL blocker. It is used primarily as an adjunctive antiepileptic agent for the treatment of PARTIAL SEIZURES, with or without secondary generalization.
zonisamide : A 1,2-benzoxazole compound having a sulfamoylmethyl substituent at the 3-position.
Protein Aggregation, Pathological: A biochemical phenomenon in which misfolded proteins aggregate either intra- or extracellularly. Triggered by factors such as MUTATION; POST-TRANSLATIONAL MODIFICATIONS, and environmental stress, it is generally associated with ALZHEIMER DISEASE; PARKINSON DISEASE; HUNTINGTON DISEASE; and TYPE 2 DIABETES MELLITUS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The anti-epileptic agent zonisamide (ZNS) has been shown to exert protective effects in neurotoxin-based mouse models of Parkinson disease." | 3.80 | Zonisamide attenuates α-synuclein neurotoxicity by an aggregation-independent mechanism in a rat model of familial Parkinson's disease. ( Arawaka, S; Fukushima, S; Kato, T; Koga, K; Koyama, S; Sasaki, A; Sato, H, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Arawaka, S | 1 |
| Fukushima, S | 1 |
| Sato, H | 1 |
| Sasaki, A | 1 |
| Koga, K | 1 |
| Koyama, S | 1 |
| Kato, T | 1 |
1 other study available for zonisamide and Protein Aggregation, Pathological
| Article | Year |
|---|---|
Zonisamide attenuates α-synuclein neurotoxicity by an aggregation-independent mechanism in a rat model of familial Parkinson's disease.
Topics: alpha-Synuclein; Animals; Cell Count; Dependovirus; Disease Models, Animal; Dopaminergic Neurons; Is | 2014 |